Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a medical device company focused on the commercialization of our flagship product, MelaFind®, and the further design and development of MelaFind® and our technology. MelaFind®is a non-invasive, point-of-care (i.e. in the doctor’s office) instrument to aid in the detection of melanoma. MelaFind®, features a hand-held component that emits light of multiple wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated classification algorithms, ‘trained’ on our proprietary database of melanomas and benign lesions, to provide information to assist in the management of the patient’s disease, including information useful in the decision whether to biopsy the lesion. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-0.74 |
| Quarterly EPS Est: | -0.17 |
| PEG Ratio: | .00 |
|
Mean Recommendation: View Summary / View All |
1 |
Data is provided by Zacks Investment Research

